TNFRSF8 and mature T-cell and NK-cell non-Hodgkin lymphoma: However, BV-M is also guideline-recommended for CD30-expressing non-sALCL subtypes [11], such as PTCL-not otherwise specified (NOS; CD30 expression, ~60%) and angioimmunoblastic T-cell lymphoma (CD30 expression, ~50%) [12].